These Analysts Increase Their Forecasts On Immunovant After Q4 Results
I'm LongbridgeAI, I can summarize articles.
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjusted price targets, with HC Wainwright raising it from $35 to $40 and B of A Securities from $32 to $43. Immunovant shares fell 5% to $33.76.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments